

1 **ACCEPTED VERSION**

2 **LICENCE CC by-nc-nd**

3 **Please cite as:** Di Lodovico S, Bacchetti T, D'Ercole S, Covone S, Petrini M, Di Giulio M, Di
4 Fermo P, Diban F, Ferretti G, Cellini L. Complex Chronic Wound Biofilms Are Inhibited *in*
5 *vitro* by the Natural Extract of *Capparis spinose*. Front Microbiol. 2022 Apr 11;13:832919. doi:
6 10.3389/fmicb.2022.832919. PMID: 35479636; PMCID: PMC9035792.

7

8

9

10

11 **Complex chronic wound biofilms are inhibited *in vitro* by the natural**
12 **extract of *Capparis spinose***

13

14 **Silvia Di Lodovico¹, Tiziana Bacchetti², Simonetta D’Ercole³, Sara Covone¹, Morena Petrini³,**
15 **Mara Di Giulio¹, Paola Di Fermo¹, Firas Diban¹, Gianna Ferretti⁴, Luigina Cellini^{1*}**

16

17 ¹Department of Pharmacy, University “G. d’Annunzio” Chieti-Pescara, 66100, Chieti, Italy.

18 ²Department of Life and Environmental Sciences, Polytechnic University of Marche, 60131, Ancona,
19 Italy.

20 ³Department of Medical, Oral and Biotechnological Sciences, University “G. d’Annunzio” Chieti-
21 Pescara, 66100, Chieti, Italy.

22 ⁴Department of Clinical Science, Research Center of Health Education and Health Promotion,
23 Polytechnic University of Marche, 60131, Ancona, Italy.

24

25 *** Correspondence:**

26 Luigina Cellini

27 l.cellini@unich.it

28 Tel.:+39 08713554560

29

30

31 Running title: Chronic-wound-biofilms inhibited by *Capparis spinose*

32 **Keywords:** *Capparis spinose*, antimicrobial and anti-virulence actions, Dual-species biofilm, Lubbock
33 Chronic Wound Biofilm model, *S. aureus*, *P. aeruginosa*, *C. albicans*.

34

35 Number of Words: 4932

36 Number of Figures: 4

37 Number of Tables: 3

38

39

40

41

42

43 **Abstract**

44 Resistant wound microorganisms are becoming an extremely serious challenge in the process of
45 treating infected chronic wounds, leading to impaired healing. Thus, additional approaches should be
46 taken into consideration to improve the healing process. The use of natural extracts can represent a
47 valid alternative to treat/control the microbial infections in wounds. This study investigates the
48 antimicrobial/anti-virulence effects of *Capparis spinose* aqueous extract against the main chronic
49 wound pathogens: *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Candida albicans*. The extract
50 shows phenolic characterization with the rutin ($1.8 \pm 0.14\mu\text{g}/\text{mg}$) as the major compound and
51 antibacterial effect against bacteria (*S. aureus* PECHA 10 MIC 6.25%; *P. aeruginosa* PECHA 4 MIC
52 12.50%) without action against *C. albicans* (MIC and MFC $\geq 50\%$). *Capparis spinose* also shows a
53 significant anti-virulence effect in terms of anti-motility/anti-biofilm actions. In particular, the extract
54 acts: i) on *P. aeruginosa* both increasing its swimming and swarming motility favouring the planktonic
55 phenotype and reducing its adhesive capability; ii) on *S. aureus* and *P. aeruginosa* biofilm formation
56 reducing both the biomass and CFU/ml. Furthermore, the extract significantly displays the reduction
57 of a dual species *S. aureus* and *P. aeruginosa* Lubbock Chronic Wound Biofilm, a complex model that
58 mimics the realistic *in vivo* microbial spatial distribution in wounds. The results suggest that *C. spinose*
59 aqueous extract could represent an innovative eco-friendly strategy to prevent/control the wound
60 microbial infection.

61

62 1 INTRODUCTION

63 The increase and rapid spread of antimicrobial resistant wounds microorganisms hinders the
64 management of microbial infections and delays wound healing. The wound microbial colonization of
65 wound is the most frequent poly-microbial colonization, involving both aerobic and anaerobic
66 pathogen microorganisms including bacteria and yeasts. Among the detected pathogens,
67 *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Candida albicans* and beta-hemolytic streptococci
68 are the primary cause of delayed wound healing and infection (Bowler et al, 2001). In particular, *S.*
69 *aureus* and *P. aeruginosa* are the main wound bacterial isolates playing an important role in the
70 development of poly-microbial biofilms (DeLeon et al., 2014; Di Giulio et al., 2020).

71 *Staphylococcus aureus* is the most problematic bacterium in wound infections (Tong et al.,
72 2015) with a high incidence affecting the management practices. As reported by Nakamura et al.
73 (2014), the blood stream infection by *S. aureus* is an important risk factor of wound infection.
74 *Staphylococcus aureus* is able to express various virulence factors that facilitate cell adhesion and host
75 response. In fact, the microorganism binds fibronectin, collagen, fibrinogen, laminin and elastin and
76 thanks to its coagulase activity, it produces a fibrin network that represents a scaffold on which bacteria
77 can adhere forming biofilm (Arciola et al., 2005; Yung et al., 2021). Alves et al. (2018) demonstrated
78 that *S. aureus* acts as pioneer for the attachment of *P. aeruginosa* that, in turn, promotes an invasive
79 phenotype in *S. aureus*.

80 *Pseudomonas aeruginosa* is another important pathogen responsible for infections difficult to
81 treat including skin diseases. If the wound is not properly treated, *P. aeruginosa* is able to change the
82 infection type from local to systemic. The increasing in multidrug resistant *P. aeruginosa* strains
83 together with their capability to form biofilm represent a challenge for the treatment (Yang et al., 2019).
84 In addition, the dynamic relationship among swimming, swarming and twitching motility represents a
85 significant virulence bacterium trait, interfering with the biofilm formation (Zolfaghar et al., 2003).
86 Finally, in wound biofilms, also *C. albicans* provides a synergistic microbial complex with bacteria
87 (Di Giulio et al., 2018).

88 Chronic wound infections are persistent and very hard to eradicate due to the poly-microbial
89 biofilm and the increasing resistant/tolerant microorganisms against traditional treatments. Orazi et al.
90 (2017) reported that, in a poly-microbial biofilm, exoproducts of *P. aeruginosa* reduce the

91 susceptibility of *S. aureus* to vancomycin and tobramycin and the release of N-acetyl glucosamine
92 (GlcNAc) by *S. aureus* stimulates the *P. aeruginosa* quinolones signal (PQS) that is responsible for the
93 production of its virulence factors (e.g. pyocyanin, elastase, rhamnolipids and HQNO) and quorum
94 sensing. The increase of multidrug resistant wound strains today represents an important worldwide
95 challenge and new treatment strategies are urgent. New approaches have been developed to act
96 interfering with the ability of the bacteria to produce virulence factors, such as the factors produced
97 during growth as biofilms, which promote resistance to common drugs.

98 In this scenario, natural compounds could represent innovative approaches, as adjuvants and
99 alternatives to antibiotics in the drainage or debridement to remove sloughed and devitalized tissues
100 which cause slow wound healing (Di Giulio et al., 2020).

101 Different natural compounds are proposed to treat microbial proliferation in the wound.
102 Bioactive and antimicrobial properties of extracts of plant phenolic compounds against human
103 pathogens have been widely studied to characterize and develop new medical and pharmaceutical
104 products (Tungmunnithum et al., 2018). In particular, the phenolic fraction of natural compounds is
105 responsible of the organoleptic and biological effects, such as antimicrobial and anti-biofilm effects
106 (Di Lodovico et al., 2020).

107 Among the different medicinal plants, *Capparis spinose* deserves to be better investigated for its
108 biological properties. *Capparis spinose* (*C. spinosa*), belonging to the *Capparidaceae* family, is widely
109 found in the Mediterranean area (especially in France, Spain, Italy and Algeria) (Rahimi et al., 2020;
110 Al-Snafi, 2015). It is a perennial spiny bush that bears rounded, fleshy leaves and big white to pinkish-
111 white flowers. *Capparis spinose* has been used as traditional herbal remedy since ancient times for its
112 beneficial effects on human diseases such as splenomegaly, mental disorders, tubercular glands,
113 rheumatoid arthritis, gut and skin disease. Mahboubi et al. (Mahboubi and Mahboubi, 2014) showed
114 that the aqueous extracts from roots of *C. spinose* displays a remarkable antimicrobial activity
115 including *Staphylococcus* spp., *Escherichia coli*, *Helicobacter pylori*, *Candida* spp., *Aspergillus niger*.

116 The aim of this study is to investigate the antimicrobial and anti-virulence effects of *C. spinose*
117 aqueous extract against the main chronic wound pathogens. The anti-virulence analysis is performed
118 by evaluating *C. spinose* anti-motility/twitching and anti-biofilm actions. The poly-microbial biofilm
119 is also analysed by using the Lubbock Chronic Wound Biofilm (LCWB) model that mimics the realistic
120 microbial spatial proliferation in wounds. This *in vitro* model is widely recognized as more closely
121 resembling to the *in vivo* human wound environment including the wound simulating medium, the
122 fibrin network produced by *S. aureus* and the realistic nutrient and the oxygen gradient (Thaarup and
123 Bjarnsholt 2021). This suitable *in vitro* model represents a pivotal preliminary screen useful to translate
124 into *in vivo* detections.

125 The proposed study can be defined as “green research” in line with the identification of novel
126 strategies to overcome antimicrobial resistance and for the low environmental impact in the aqueous
127 extraction that is widely diffused in the Mediterranean area.

128 The innovative aspect of this work is to propose a valid and eco-friendly not-antibiotic strategy
129 to prevent and control wound microbial infections, strongly highlighting the antimicrobial and anti-
130 virulence actions of *C. spinose* aqueous extract.

131

132 **2 MATERIALS AND METHODS**

133 **2.1 Bacterial cultures**

134 Anonymised clinical *Staphylococcus aureus* PECHA 10, *Pseudomonas aeruginosa* PECHA 4 and
135 *Candida albicans* X3 strains (Di Giulio et al., 2018; Di Giulio et al., 2020) were used for this study.
136 The strains were isolated from chronic wounds of patients that gave their informed consent for the
137 study. The study was approved by the Inter Institutional Ethic Committee of University “G.
138 d’Annunzio” Chieti-Pescara, Chieti, Italy (ID n. richycnvw). The strains were characterized for their
139 susceptibility to antibiotics and, in particular, *S. aureus* PECHA 10 and *P. aeruginosa* PECHA 4 were

140 resistant strains (**Table 1S**). All the methods were performed in accordance with the relevant guidelines
141 and regulations. For the experiments, bacteria were cultured in Trypticase Soy Broth (TSB, Oxoid,
142 Milan, Italy) and incubated at 37°C overnight in aerobic condition and then refreshed for 2h at 37°C
143 in an orbital shaker. Then the broth cultures were standardized to Optical Density at 600nm (OD₆₀₀) =
144 0.125. The broth culture of *Candida albicans*, grown on Sabouraud dextrose agar (SAB, Oxoid, Milan,
145 Italy) was prepared in RPMI 1640 (Sigma-Aldrich, Milan, Italy) plus 2% glucose and standardized to
146 OD₆₀₀ = 0.15.

147

148 **2.2 Chemicals**

149 Gallic acid, Catechin, Chlorogenic acid, p-OH benzoic acid, Vanillic acid, Epicatechin, Syringic acid,
150 3-OH benzoic acid, 3-OH-4-MeO benzaldehyde, p-coumaric acid, Rutin, Sinapinic acid, t-ferullic acid,
151 Naringin, 2,3-diMeO benzoic acid, Benzoic acid, o-coumaric acid, Quercetin, Harpagoside, t-cinnamic
152 acid, Naringenin, Carvacrol were purchased from Sigma Aldrich (Milan, Italy). Methanol (HPLC-
153 grade) and formic acid (99%) were obtained from Carlo Erba Reagenti (Milan, Italy).

154 **2.3 Extract preparation**

155 Plants of *C. spinose subsp. rupestris* have been growing in Borgo Cisterna (Santa Lucia Cisterna,
156 Macerata Feltria, PU, Italy) and managed by Agency for Food Service Industry in the Marche
157 (ASSAM), an institution involved in the implementation of programs for the protection of biodiversity
158 for agriculture of Marche Region in relation to the Regional Law No. 12 “Protection of animal and
159 plant genetic resources of the Marche” approved June 2003. The law protects the genetic resources that
160 are locally grown within the region. The flower bods used in this study have been kindly provided by
161 Mario Gallarani and his family that grow *C. spinose subsp. rupestris* in Borgo Cisterna (Santa Lucia
162 Cisterna, Macerata Feltria, PU, Italy). Plants of *C. spinose subsp. rupestris* has been registered to
163 the Regional Register of Biodiversity of Marche Region No.70 of the Vegetal Section, Herbaceous
164 Species. The use of *C. spinose* was in agreement with the IUCN Policy Statement on Research
165 Involving Species at Risk of Extinction and the Convention on the Trade in Endangered Species of
166 Wild Fauna and Flora. *Capparis spinose* flower bods were washed, frozen at -20°C, freeze-dried and
167 shredded. One g of the powdered sample was incubated with 100 ml ultra-filtered water at 80°C for 10
168 minutes (Eddouks et al., 2017). Thereafter, the aqueous extract was filtered by Millipore filter
169 (Millipore 0.2 mm) to remove particulate matter.

170

171 **2.4 HPLC analyses**

172 HPLC analyses were performed on Waters liquid chromatograph equipped with a model 600 solvent
173 pump and a 2996 photodiode array detector and Empower v.2 Software (Waters Spa, Milford, MA,
174 USA) was used for acquisition of data. C18 reversed-phase packing column (Prodigy ODS(3), 4.6×150
175 mm, 5 µm; Phenomenex, Torrance, CA, USA) was used for the separation and the column was
176 thermostated at 30±1°C using a Jetstream2 Plus column oven. The UV/Vis acquisition wavelength was
177 set in the range of 200-500 nm. The quantitative analyses were achieved at maximum wavelength for
178 each compounds. The injection volume was 20 µl. The mobile phase was directly on-line degassed by
179 using Biotech DEGASi, mod. Compact (LabService, Anzola dell’Emilia, Italy). Gradient elution was
180 performed using the mobile phase water-acetonitrile (93:7, v/v, 3% acetic acid) (Zengin et al., 2017).
181 The sample solutions were centrifuged and the supernatant was injected into HPLC.

182 The phenolics stock solutions were prepared at concentration of 1 mg/ml in a final volume of 10 ml of
183 methanol. Working solutions of mixed standards at different concentrations obtained by dilution in
184 mobile phase, were injected into the HPLC-UV/Vis system.

185 The lyophilized extract sample was weighted and dissolved in mobile phase and 20 µl injected into
186 HPLC-UV/Vis system. For over range samples, 1:10 dilution factor was applied.

187 **2.5 Assessment of total phenolic and flavonoid content and antioxidant activity**

188 Total phenolic (TP) content in *C. spinose* has been evaluated by Folin–Ciocalteu assay (Ainsworth and
189 Gillespie 2007). Total flavonoid (TF) content in *C. spinose* was measured by spectrophotometry with
190 aluminum chloride (AlCl₃) as the reagent according to Kim et al. (2003) TP and TF levels were
191 expressed as milligrams of gallic acid equivalent (GAE) per 100 g of dry weight of *C. spinose* (mg
192 GAE/100 gdw) and milligrams of catechin equivalent (CE) per 100 g of dry weight of *C. spinose* (mg
193 CE/100 gdw), respectively.

194 Total antioxidant capacity (TAC) of *C. spinose* was determined by oxygen radical absorbance capacity
195 (ORAC) assay, using fluorescein, as fluorescent probe, and 2,2'-azobis (2-methylpropionamide)
196 dihydrochloride (AAPH), as oxidizing agent (Gillespie et al., 2007). Trolox was used to calibrate the
197 assay. The final ORAC values were calculated using the net area under the curve (AUC) of decay.
198 Results were expressed as Trolox equivalents per 100 g of dry *C. spinose* weight (mmol TE/100 gdw).
199

200 **2.6 *Capparis spinose* aqueous extract antimicrobial assays**

201 The *C. spinose* aqueous extract MIC was performed against *S. aureus* PECHA 10, *P. aeruginosa*
202 PECHA 4 and *C. albicans* X3 by microdilution method according to CLSI guidelines (2018). *Capparis*
203 *spinose* aqueous extract stock solution was diluted in Mueller Hinton Broth II cation adjusted (MHB,
204 Oxoid, Milan, Italy) for bacteria and in RPMI 1640 plus 2% glucose for *C. albicans* X3 at the final
205 concentration from 50% to 0.78%. MBCs/MFCs were determined by sub-culturing 10 µl of
206 suspensions from the MICs on Mueller Hinton agar (MHA, OXOID, Milan, Italy) for bacteria and on
207 Sabouraud Dextrose agar (SAB, OXOID, Milan, Italy) for *C. albicans*.

208 As control, Amikacin and Amphotericin-B MICs were performed for bacteria and *C. albicans* X3,
209 respectively.
210

211 **2.7 *Capparis spinose* aqueous extract anti-virulence assays**

212 The anti-virulence analysis of *C. spinose* aqueous extract was performed by evaluating its effect on *P.*
213 *aeruginosa* PECHA 4 motility (swimming and swarming), *P. aeruginosa* PECHA 4 twitching, *S.*
214 *aureus* PECHA 10 and *P. aeruginosa* PECHA 4 biofilm formation.

215 **2.7.1 Effect on *P. aeruginosa* PECHA 4 motility**

216 The *C. spinose* aqueous extract capability to interfere with the *P. aeruginosa* PECHA 4 motility was
217 determined by swarming and swimming motility. Briefly, according to Abraham et al. (2011), for the
218 swarming motility, the standardized cultures were inoculated at the center of swarming plates
219 containing 1% peptone, 0.5% NaCl, 0.5% agar and 0.5% D-glucose with the extract at sub-MICs. For
220 swimming motility, standardized cultures were inoculated at the center of plates containing 1%
221 tryptone, 0.5% NaCl and 0.3% agar and extract at sub-MICs. Plates were incubated at 37°C for 24h
222 and bacterial halos were recorded.
223

224 **2.7.2 Effect on *P. aeruginosa* PECHA 4 twitching**

225 The capability of *C. spinose* aqueous extract to interfere with the *P. aeruginosa* PECHA 4 pilus
226 retraction was determined by twitching assay. For the cultural analysis, cultures were inoculated to the
227 bottom of the twitching plates consisting of 10 g/l tryptone, 5 g/l yeast extract, 10 g/l NaCl, 1% agar
228 with the extract at sub-MICs. Plates were incubated at 37°C for 24h and then the agar was removed
229 and the halo was stained with 0.1% Crystal Violet and measured (Turnbull and Whitchurch, 2014).
230 For RT-PCR *pilT* gene expression, *P. aeruginosa* PECHA 4 RNA was extracted using the RNeasy
231 mini kit (Qiagen, Milan, Italy), according to the manufacturer's instructions. cDNA was generated
232 using the iScript cDNA Synthesis Kit (Bio-Rad, Milan, Italy) and then stored at -20°C until use. For
233 the quantitative PCR, the oligonucleotide used primers were: *pilT* Fwd:
234 ACCGACTTCTCCTTCGAGGT; *pilT* Rev: GAGGGAATGGTCCGGAATAC (Cowles and Gitai,

235 2010); the housekeeping gene 5S RNA Fwd: TGACGATCATAGAGCGTTGG; 5S RNA Rsv:
236 GATAGGAGCTTGACGATGACCT (El-Sayed et al., 2020). Quantitative PCR reactions were
237 performed according to Di Fermo et al. (2020). A melting curve was used at the end to confirm only
238 one peak and only one product. Values of the threshold cycle (Ct) and relative expression level were
239 normalized by the Δ CT method. Results were analysed using the Bio-Rad CFX Manager Software,
240 version 3.1 (Bio-Rad Laboratorie).

241 242 **2.7.3 Effect on *S. aureus* PECHA 10 and *P. aeruginosa* PECHA 4 biofilm formation**

243 Considering the ineffectiveness of *C. spinose* against *C. albicans* X3, the anti-biofilm effect was not
244 detected. *Capparis spinose* aqueous extract anti-biofilm effect at sub-MICs was evaluated on *S. aureus*
245 PECHA 10 and *P. aeruginosa* PECHA 4 biofilms formation in terms of: i) biomass quantification, ii)
246 CFU/ml and iii) cells viability.

247 For biomass quantification, standardized cultures in TSB (Oxoid) plus 0.5% (vol/vol) glucose were
248 inoculated in 96-well flat-bottom microtiter plates in presence of 1/2, 1/4, 1/8 MIC or without (control)
249 the extract. Plates were incubated at 37°C for 24h in aerobic condition. After incubation, dry-biofilms
250 were stained with 0.1% Crystal Violet and quantified according to Di Lodovico et al. (2020).

251 For CFU/ml determination, after 24h, each well was washed with PBS and adhered bacteria were
252 scraped off and resuspended in 200 μ l of PBS, transferred to test tubes, vortexed for 2 min, diluted and
253 spread on Mannitol Salt (MSA, OXOID, Milan, Italy) agar for *S. aureus* PECHA 10 and on Cetrimide
254 (CET, OXOID, Milan, Italy) for *P. aeruginosa* PECHA 4. Plates were incubated for 24h at 37°C
255 (D'Ercole et al., 2020). Microscopic observations with Live/Dead staining prior to spreading confirmed
256 the presence of disaggregated viable cells.

257 Cells viability was evaluated by using Live/Dead staining (Molecular Probes Inc., Invitrogen, San
258 Giuliano Milanese, Italy) according to Di Lodovico et al. (Turnbull and Whitchurch, 2014; Di
259 Lodovico et al., 2019). The number of viable and dead cells was determined by using an image analysis
260 software (LEICA QWin) through the examination of at least 10 random fields of view and the counts
261 were repeated independently by three blinded microbiologists (Di Lodovico et al., 2020).

262 263 **2.7.4 Effect on dual-species biofilm, Lubbock Chronic Wound Biofilm (LCWB)**

264 To evaluate the effect of *C. spinose* aqueous extract in a dual-species *S. aureus* and *P. aeruginosa*
265 biofilm, in forming LCWB was prepared according to Di Giulio et al. (2020). Briefly, 100 μ l of extract
266 at a final concentration of 3.12%, that corresponded to 1/2 MIC of *S. aureus* PECHA 10, or 100 μ l of
267 Amikacin (AMK, as a reference) at a final concentration of 8 mg/l or 100 μ l of PBS (for control) were
268 added to the Lubbock medium containing Brucella Broth (BB, Oxoid, Milan, Italy) with 0.1% agar
269 bacteriological, 50% porcine plasma (Sigma Aldrich, Milan, Italy), 5% horse erythrocytes (BBL,
270 Microbiology System, Milan, Italy), 2% Foetal Calf serum (Biolife Italiana, Milan, Italy), *S. aureus*
271 and *P. aeruginosa*, grown in TSB (Oxoid) (Di Giulio et al., 2020). The test tubes were incubated for
272 48h at 37°C and then the *S. aureus* PECHA 10 and *P. aeruginosa* PECHA 4 CFUs per mg of LCWB
273 were determined (Di Giulio et al., 2020).

274 275 **2.8 Statistical analysis**

276 Data was obtained from at least three independent experiments performed in duplicate. Data was shown
277 as the means \pm standard deviation. Differences between groups were assessed with one-way analysis
278 of variance (ANOVA). *P* values \leq 0.05 were considered statistically significant.

279 280 **3 RESULTS**

281 This study evaluates the antimicrobial and anti-virulence properties of a well-characterized *C. spinose*
282 aqueous extract against microorganisms isolated from chronic wounds.

283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331

3.1 HPLC analysis

Only quantifiable phenolic compounds greater than the limit of quantification (LOQ = 0.20 µg/ml) are shown in the **Table 1**. All other compounds are to be understood as not detected or below the detection limit (LOD = 0.10 µg/ml).

3.2 Assessment of total phenolic and flavonoid content and antioxidant activity

Total phenolic (TP) and Total flavonoid (TF) levels in *C. spinose* aqueous extract are 1.6 ± 0.1 g GAE/100 g and 91.1 ± 19.3 mg CE/100 g, respectively. Total antioxidant capacity, evaluated by ORAC assay, is 50.8 ± 8.4 mmol TE/100g.

3.3 *Capparis spinose* aqueous extract antimicrobial assays

Table 2 shows the MIC and the MBC/MFC values of *C. spinose* aqueous extract against *S. aureus*, *P. aeruginosa* and *C. albicans* clinical isolates.

According to *C. spinose* aqueous extract gallic acid and catechin equivalent analysis, the *S. aureus* MIC corresponds to 0.78 mg GAE/ml and 0.11 mg CE/ml and the MBC corresponds to 1.56 mg GAE/ml and 0.22 mg CE/ml. The *P. aeruginosa* MIC corresponds to 1.56 mg GAE/ml and 0.22 mg CE/ml and the MBC corresponds to 3.12 mg GAE/ml and 0.44 mg CE/ml. For *C. albicans*, the MIC and the MFC are major than 6.25 mg GAE/ml and 0.90 mg CE/ml.

Capparis spinose aqueous extract shows a relevant antibacterial effect against the tested bacterial strains.

Considering the ineffectiveness of *C. spinose* aqueous extract against *C. albicans* (MIC and MFC values are more than 50%, that is the maximum percentage of the extract tested in this study), this microorganism is not included in the subsequent experiments.

3.4 *Capparis spinose* aqueous extract anti-virulence assays

3.4.1 Effect on *P. aeruginosa* PECHA 4 motility

The *C. spinose* aqueous extract displays a significant increase in the swimming and swarming motility of *P. aeruginosa*. As shown in **Figures 1A and B**, the swimming and swarming halo sizes are more than the control ones. In fact, the halo diameter of swimming motility for the control is 4 ± 1 mm whereas 10 ± 2 mm and 12 ± 2 mm are halo diameters recorded in presence of 1/4 and 1/8 MIC of *C. spinose* aqueous extract, respectively. The halos diameters for swarming motility are: 6 ± 1 mm for control, 11 ± 3 mm and 13 ± 3 mm for 1/4 and 1/8 MIC of *C. spinose* aqueous extract, respectively.

Capparis spinose aqueous extract enhances *P. aeruginosa* flagellar activation.

3.4.2 Effect on *P. aeruginosa* PECHA 4 twitching

For twitching motility, relevant percentages of halos reduction in respect to the control are obtained. As shown in **Figure 2A**, the halos diameters are 12 ± 4 mm for control and 9 ± 1 mm in presence of both 1/4 and 1/8 MIC of *C. spinose* aqueous extract with $23\% \pm 15$ of halos reduction. This data is also confirmed by RT-PCR that evaluates the *pilT* gene expression. *Capparis spinose* aqueous extract at sub-MIC concentrations reduces the *pilT* expression of 27% (**Figures 2B and C**).

Capparis spinose aqueous extract interferes with the *P. aeruginosa* pilus retraction, reducing the microorganism adhesive capability.

3.4.3 Effect on *S. aureus* PECHA 10 and *P. aeruginosa* PECHA 4 biofilm formation

The *C. spinose* aqueous extract shows a significant action in anti-biofilm formation against both *S. aureus* and *P. aeruginosa* detected strains. As shown in **Figure 3A**, the *C. spinose* aqueous extract, at sub-MIC values, significantly reduces the *S. aureus* biomass after 24h of treatment. In particular, the percentages of biomass reduction in respect to the control are: $92.21\% \pm 1.87$, $90.54\% \pm 8.38$ and

332 72.63% \pm 6.62 at 1/2, 1/4, and 1/8 MICs, respectively. **Figure 3B**, shows the *S. aureus* CFU/ml of
333 biofilm formation after treatment with sub-MICs of *C. spinose* aqueous extract for 24h. In respect to
334 the control, there is a significant CFU/ml reduction ($p < 0.05$) at 1/2 and 1/4 MICs. In presence of *C.*
335 *spinose* aqueous extract at sub-MICs, there is a relevant reduction of biofilm adhesion with remarkable
336 red cells is detected in Live/Dead images (**Figure 3C**). The cells appear less clustered with about 20%
337 of dead red cells (**Figure 3C**, histograms).

338 Regarding to the *P. aeruginosa* anti-biofilm formation activity, significant percentages of biomass
339 reduction are obtained at sub-MICs. In detail, the percentages range from 89.97% \pm 4.97 at 1/8 MIC
340 to 99.48% \pm 0.76 at 1/2 MIC (**Figure 4A**). In presence of *C. spinose* aqueous extract, significant
341 reductions ($p < 0.05$) of biomass and CFU/ml are observed. In fact, few cells are detected by CFU
342 enumeration (**Figure 4B**) and Live/Dead staining (**Figure 4C**). This significant *P. aeruginosa*
343 reduction in presence of *C. spinose* aqueous extract is confirmed by Live/Dead images (**Figure 4C**)
344 with an almost total percentage of viable cells (**Figure C** histograms).

345 *Capparis spinose* aqueous extract is able to inhibit the biofilm formation of *S. aureus* and *P.*
346 *aeruginosa* tested strains.

347 348 **3.4.4 Effect on dual-species biofilm, Lubbock Chronic Wound Biofilm (LCWB)**

349 In a poly-microbial biofilm, *C. spinose* aqueous extract significantly reduces the microbial growth. In
350 fact, in dual species *S. aureus* and *P. aeruginosa* LCWB, the CFU/mg reductions are 97.32% \pm 2.29 (p
351 < 0.05) for *S. aureus* and 99.67% \pm 0.07 ($p < 0.05$) for *P. aeruginosa* (**Table 3**). This relevant reduction
352 is alike to those obtained with the antibiotic used as reference control.

353 *Capparis spinose* aqueous extract confirms its anti-biofilm effect in the complex system LCWB
354 model with a significant capability to reduce the microbial growth.

355 **4 DISCUSSION**

356 In this study, the antimicrobial and anti-virulence activities of a characterized *C. spinose* aqueous
357 extract have been evaluated against resistant chronic wounds microorganisms. The worrying
358 phenomenon related to the antimicrobial resistance of chronic wound microorganisms is the cause of
359 treatments failure. In addition, the chronic wound infections are always associated to the poly-
360 microbial biofilm delaying the wound healing (Di Giulio et al., 2020).

361 The World Health Organization reports the use of different medicinal plants for the
362 management of health and treatment of diseases due to their bioactive components and health-
363 promoting effects (World Health Organization (WHO) 2013).

364 Caper berries contain a wide range of bioactive compounds such as alkaloids, flavonoids,
365 steroids, terpenoids, and tocopherols. Healthy properties and composition of phytonutrients of
366 *Capparis* flower buds have been recently reviewed. Levels and composition of phytonutrients are
367 influenced by different factors such as cultivars, genotypes (both cultivated and wild) and geographical
368 origin (Maldini et al., 2016, Zhang and Ma, 2018; Wojdyło et al., 2019).

369 The profile of the main phenolic compounds, detected in the present study, is in a greater part
370 in agreement with previous studies (Mollica et al., 2017; Stefanucci et al., 2018) with the exception of
371 the amount of rutin, that represents the compound in major amount. It is important to mention that the
372 phenolic profile could change according to the applied extraction technique and the extraction solvent,
373 which is confirmed by several studies in the literature (Mollica et al., 2017; Mollica et al., 2019;
374 Stefanucci et al., 2018). In particular, Stefanucci et al. (2018) demonstrated a large variability in rutin
375 concentration in *Capparis* collected in Italy, Morocco and Turkey (Mollica et al., 2017; Mollica et al.,
376 2019).

377 The studied *C. spinose* aqueous extract affects the bacterial growth without any impact on yeast
378 cells, showing a selective action against bacteria. In fact, the compound shows a significant
379 antimicrobial action against *S. aureus* and *P. aeruginosa* clinical isolates without a relevant effect

380 against *C. albicans*. The detected MIC values are in the MIC range previously found by Taguri et al.
381 (2006) who determined the MICs of 22 polyphenols against 26 species of bacteria with MIC values
382 between 0.067 and 3.200 g/l.

383 The molecular mechanisms of antibacterial action of phytochemicals, such as phenolic compounds, are
384 not yet fully understood but these compounds are known to involve many sites of action at cellular
385 level (Bouarab-Chibane et al., 2019). Several authors explained the antimicrobial activity of
386 polyphenols by modifications in the cell membrane permeability, changes in intracellular functions
387 due to interactions between the phenolic compounds and cell enzymes or by the modification of the
388 cell wall rigidity with integrity losses due to different interactions polyphenols cell membrane (Ikigai
389 et al., 1993; Stapleton et al., 2004; Taguri et al., 2006; Cushnie and Lamb, 2011). Among polyphenols,
390 the main category included in Capparis extract are anthocyanins. We suggest that the observed
391 antibacterial effect could be related to these molecules and/or the synergisms with other antioxidant
392 polyphenols such as phenolic acids, and their mixtures of different chemical forms. Moreover,
393 according to the *C. spinose* aqueous extract characterization, the rutin could be responsible for the
394 action against *S. aureus* and *P. aeruginosa* growth interfering with DNA synthesis, an antibacterial
395 mechanism of action of various flavonoids (Cushnie and Lamb 2005). In addition, as reported by
396 Cushnie et al. (2005), the flavonoids toxicity is minimal in fact, they are widely spread in edible plant
397 and beverages. However, for the *in vivo* application, the evaluation of the eventual toxic effect should
398 be done.

399 *Capparis spinose* aqueous extract displays also a relevant anti-virulence action against *P.*
400 *aeruginosa* motility/twitching and *S. aureus* and *P. aeruginosa* mono- and poly-microbial biofilms. In
401 fact, the tested extract acts both on swimming/swarming motility favouring the flagellar-mediated
402 movement and twitching motility reducing the *P. aeruginosa* adhesion. The detected significant
403 increase in flagellar biosynthesis, in respect to the control, favours the planktonic status leading to
404 enhance the bacterial movement. This effect induces a phenotype more susceptible to treatments. The
405 noticed microbial twitching reduction interferes with the *P. aeruginosa* adhesive capability. The
406 twitching motility is an important step for bacterial colonization and biofilm formation in *P. aeruginosa*
407 (Shreeram et al., 2018). In particular, the inactivation and loss of function in *pilT* produces a
408 hyperpiliation and the loss of twitching motility due to the inability of pilus fibers formation. The
409 inactivation of *pilT* determines the loss of cytotoxicity *in vitro* and the inhibition of the contact between
410 bacteria and the host cells (Shreeram et al., 2018). Here, *C. spinose* extract acts weakening the *P.*
411 *aeruginosa* adhesive capability.

412 Microbial biofilm mode of growth allows microbes to protect themselves against host immune
413 system and antimicrobial agents making biofilm related infections difficult to treat and eradicate. In
414 this study, *C. spinose* aqueous extract significantly reduces the mono and poly-microbial biofilms of
415 *S. aureus* and *P. aeruginosa* with less clustered cells. On mono-microbial biofilms, the effect is more
416 relevant against *P. aeruginosa* with a significant effect on biomass quantification and bacterial cells.
417 On *S. aureus* biofilm formation, the compound reduces the biomass production with a slow bacterial
418 growth reduction. Cosa et al. (2019) showed that the anti-biofilm effect of *C. spinose* is correlated to
419 its capability to reduce the quorum sensing (QS) regulation, reducing the bacterial virulence and
420 pathogenicity. In fact, Abram et al. (2011) showed that the *C. spinose* methanolic extract is able to
421 reduce the production of AHL-dependent QS interfering with biofilm production. In addition, the
422 authors demonstrated the capability of the extract to reduce the EPS production in different bacterial
423 pathogens. In particular, Peng et al. (2018) underline the significant role of rutin in the QS regulation
424 with AI-2 decreasing and the reduction of biofilm formation and virulence factors gene expression.

425 A very interesting result is obtained when the effect of *C. spinose* aqueous extract is detected
426 in a condition of poly-microbial biofilm that reproduces the *in vivo* spatial microbial colonization of *S.*
427 *aureus* and *P. aeruginosa* in a chronic wound. The used LCWB model represents a recognised *in vitro*
428 chronic wound system for inter-kingdom microbial species. In this model, the presence of red blood

429 cells, plasma and nutrients, mimicking the wound bed environment, promotes the *S. aureus*/*P.*
430 *aeruginosa* microbial growth, closely reproducing their spatial distribution in human-like environment.
431 In this complex dual-species microbial colonization, *C. spinose* aqueous extract expresses a significant
432 percentage of reduction of both microbial populations. This interesting data is obtained with a well-
433 recognized *in vitro* model that resembles to the *in vivo* wound environment in terms of: wound
434 simulating media, host matrix, several chosen species, 3D gradients, flow, grown on solid surface
435 (Thaarup and Bjarnsholt, 2021). As consequence, our results stimulate further studies on *in vivo* model
436 such as porcine and human models. In fact, the limitation of our model, while considering both the
437 presence of the most important chronic wound factors and the easy reproducibility with ethical sound,
438 is the unshared interaction between the immune system and microorganisms. The complex and
439 dynamic events related to the immune host defence should be take into account in future studies (de
440 Bont et al., 2019; Sabbatini et al., 2021).

441 In conclusion, the obtained findings suggest the capability of *C. spinose* aqueous extract to
442 inhibit the growth and virulence of *P. aeruginosa* PECHA 4 and *S. aureus* PECHA 10 chronic wound
443 microorganisms. The significant antimicrobial and anti-virulence properties make the *C. spinose* a
444 good candidate for the study of novel medicaments in the prevention and control of chronic wound
445 microorganisms.

446 *Capparis spinose* aqueous extract could represent a valid eco-friendly suggestion to overcome
447 the worrying antimicrobial resistance phenomenon.

448

449 **ADDITIONAL INFORMATIONS**

450 Correspondence and requests for materials should be addressed to L.C.

451 **CONFLICT OF INTEREST**

452 The authors declare that the research was conducted in the absence of any commercial or financial
453 relationships that could be construed as a potential conflict of interest.

454 **AUTHOR CONTRIBUTION**

455 All authors made significant contributions to this article and participated actively in the conception and
456 design of the experiments. S.D.L., M.D.G., S.D.E., P.D.F., F.D., conducted the microbiology
457 experiments. S.C., T.B., G.F., performed *Capparis spinose* characterization. M.P, S.D.L., performed
458 data analysis. S.D.L., L.C., wrote the manuscript. M.D.G., L.C., G.F., contributed to discussing the
459 results and critical review of the manuscript. All authors read and approved the final manuscript.

460 **FUNDING**

461 This study was supported by Prof. Luigina Cellini and Prof. Mara Di Giulio FAR 2020 and in part by
462 Research Grant PRIN 2017 SFBFER from MIUR, Italy.

463 **ACKNOWLEDGMENTS**

464 The authors acknowledge Gloria Magi and Arianna Rapagnetta for their technical contribution. The
465 authors also thank Ambra Micheletti from Agency for Food Service Industry in the Marche (ASSAM)
466 region, Italy, for supporting her competence in the study and Mario Gallarani and his family for
467 cultivating *C. spinose subsp. rupestris* for kindly giving us the flower bods used in this study.

468 The study was supported by Programma di Sviluppo Rurale 2014-2020 Europa/Regione Marche.

469 The authors acknowledge Olivetta Del Bianco for English revision.

470

471 **REFERENCES**

472 Abraham, S. V. P. I., Palani, A., Ramaswamy, B. R., Shunmugiah, K. P., and Arumugam, V. R.
473 (2011). Antiquorum sensing and antibiofilm potential of *Capparis spinosa*. *Arch. Med.*
474 *Res.* 42(8), 658–668. <https://doi.org/10.1016/j.arcmed.2011.12.002>
475 Ainsworth, E. A., and Gillespie, K. M. (2007). Estimation of total phenolic content and other
476 oxidation substrates in plant tissues using Folin-Ciocalteu reagent. *Nat. Protoc.* 2(4), 875–
477 877. <https://doi.org/10.1038/nprot.2007.102>
478 Al-Snafi, A. E. (2015). The chemical constituents and pharmacological effects of *Capparis spinose*
479 - an overview. *Ind. J. Pharmaceutic. Sci. Res.* 5(2), 93–100. e-ISSN: 2248-9126
480 Alves, P. M., Al-Badi, E., Withycombe, C., Jones, P. M., Purdy, K. J., and Maddocks, S. E. (2018).
481 Interaction between *Staphylococcus aureus* and *Pseudomonas aeruginosa* is beneficial for
482 colonization and pathogenicity in a mixed biofilm. *Pathog. Dis.* 76(1).
483 <https://doi.org/10.1093/femspd/fty003>
484 Arciola, C. R., Campoccia, D., Gamberini, S., Baldassarri, L., and Montanaro, L. (2005).
485 Prevalence of *cna*, *fnbA* and *fnbB* adhesin genes among *Staphylococcus aureus* isolates from
486 orthopedic infections associated to different types of implant. *FEMS Microbiol. Let.* 246(1),
487 81–86. <https://doi.org/10.1016/j.femsle.2005.03.035>
488 Bouarab-Chibane, L., Forquet, V., Lantéri, P., Clément, Y., Léonard-Akkari, L., Oulahal, N., et al.
489 (2019). Antibacterial properties of polyphenols: characterization and QSAR (Quantitative
490 Structure–Activity Relationship) models. *Front. Microbiol.* 10, 829.
491 <https://doi.org/10.3389/fmicb.2019.00829>
492 Bowler, P. G., Duerden, B. I., and Armstrong, D. G. (2001). Wound microbiology and associated
493 approaches to wound management. *Clin. Microbiol. Rev.* 14(2), 244–269.
494 <https://doi.org/10.1128/CMR.14.2.244-269.2001>
495 Clinical and Laboratory Standards Institute CLSI. (2018). *Methods for dilution antimicrobial*
496 *susceptibility tests for bacteria that grow aerobically* 11th edn. (M07-Ed11 and M100-Ed28
497 Package of 2 Docs, Wayne, PA
498 Cosa, S., Chaudhary, S. K., Chen, W., Combrinck, S., and Viljoen, A. (2019).
499 Exploring common culinary herbs and dices as potential anti-quorum sensing agents.
500 *Nutrients.* 11(4), 739. <https://doi.org/10.3390/nu11040739>
501 Cowles, K. N., and Gitai, Z. (2010). Surface association and the *MreB* cytoskeleton regulate pilus
502 production, localization and function in *Pseudomonas aeruginosa*. *Mol. Microbiol.* 76(6),
503 1411–1426. <https://doi.org/10.1111/j.1365-2958.2010.07132.x>
504 Cushnie, T. P., and Lamb, A. J. (2005). Antimicrobial activity of flavonoids. *Int J Antimicrob*
505 *Agents.* 26(5), 343–356. <https://doi.org/10.1016/j.ijantimicag.2005.09.002>
506 Cushnie, T. P. T., and Lamb, A. J. (2011). Recent advances in understanding the antibacterial
507 properties of flavonoids. *Int. J. Antimicrob. Agents* 38(2), 99–107.
508 <https://doi.org/10.1016/j.ijantimicag.2011.02.014>
509 de Bont, C. M., Boelens, W. C., and Pruijn, G. J. M. (2019). NETosis, complement, and coagulation:
510 a triangular relationship. *Cell Mol Immunol.* 16(1), 19–27. <https://doi.org/10.1038/s41423-018-0024-0>
511
512 D'Ercole, S., Di Fermo, P., Di Giulio, M., Di Lodovico, S., Di Campli, E., Scarano, A., et al. (2020).
513 Near-infrared NIR irradiation and sodium hypochlorite: an efficacious association to counteract
514 the *Enterococcus faecalis* biofilm in endodontic infections. *J. Photochem. Photobiol. B.* 210,
515 111989. <https://doi.org/10.1016/j.jphotobiol.2020.111989>
516 DeLeon, S., Clinton, A., Fowler, H., Everett, J., Horswill, A. R., and Rumbaugh, K. P. (2014).
517 Synergistic interactions of *Pseudomonas aeruginosa* and *Staphylococcus aureus* in an *in vitro*
518 wound model. *Infect. Immun.* 82(11), 4718–4728. <https://doi.org/10.1128/IAI.02198-14>
519 Di Fermo, P., Di Lodovico, S., Amoroso, R., De Filippis, B., D'Ercole, S., Di Campli, E., et al.
520 (2020). Searching for new tools to counteract the *Helicobacter pylori* resistance: the positive

- 521 action of resveratrol derivatives. *Antibiotics (Basel)* 9(12),
522 891. <https://doi.org/10.3390/antibiotics9120891>
- 523 Di Giulio, M., Zappacosta, R., Di Lodovico, S., Di Campli, E., Siani, G., Fontana, A., et al. (2018).
524 Antimicrobial and antibiofilm efficacy of Graphene Oxide against chronic wound
525 microorganisms. *Antimicrob. Agents Chemother.* 62(7), e00547-18.
526 <https://doi.org/10.1128/AAC.00547-18>
- 527 Di Giulio, M., Di Lodovico, S., Fontana, A., Traini, T., Di Campli, E., Pilato, S., et al. (2020).
528 Graphene Oxide affects *Staphylococcus aureus* and *Pseudomonas aeruginosa* dual species
529 biofilm in Lubbock Chronic Wound Biofilm model. *Sci. Rep.* 10(1), 18525.
530 <https://doi.org/10.1038/s41598-020-75086-6>
- 531 Di Lodovico, S., Menghini, L., Ferrante, C., Recchia, E., Castro-Amorim, J., Gameiro, P., et al.
532 (2020). Hop extract: an efficacious antimicrobial and anti-biofilm agent against multidrug-
533 resistant Staphylococci strains and *Cutibacterium acnes*. *Front. Microbiol.* 11, 1852.
534 <https://doi.org/10.3389/fmicb.2020.01852>
- 535 Di Lodovico, S., Napoli, E., Di Campli, E., Di Fermo, P., Gentile, D., Ruberto, G., et al. (2019).
536 *Pistacia vera* L. oleoresin and levofloxacin is a synergistic combination against resistant
537 *Helicobacter pylori* strains. *Sci Rep.* 9(1), 4646. <https://doi.org/10.1038/s41598-019-40991-y>
- 538 Di Lodovico, S., Gasparri, F., Di Campli, E., Di Fermo, P., D'Ercole, S., Cellini, L., et al. (2020).
539 Prebiotic combinations effects on the colonization of Staphylococcal skin strains.
540 *Microorganisms* 9(1), 37. <https://doi.org/10.3390/microorganisms9010037>
- 541 Eddouks, M., Lemhadri, A., Hebi, M., El Hidani, A., Zeggwagh, N. A., El Bouhali, B., Lhoussaine,
542 Hajji, L., et al. (2017). *Capparis spinosa* L. aqueous extract evokes antidiabetic effect in
543 streptozotocin-induced diabetic mice. *Avicenna J. Phytomed.* 7(2), 191–198.
544 PMID: PMC5355824
- 545 El-Sayed, N. R., Samir, R., Abdel-Hafez, L. J. M., and Ramadan, M. A. (2020). Olive leaf extract
546 modulates quorum sensing genes and biofilm formation in multi-drug resistant *Pseudomonas*
547 *aeruginosa*. *Antibiotics (Basel)* 9(9), 526. <https://doi.org/10.3390/antibiotics9090526>
- 548 Gillespie, K. M., Chae, J. M., and Ainsworth, E. A. (2007). Rapid measurement of total antioxidant
549 capacity in plants. *Nat. Protoc.* 2(4), 867–870. <https://doi.org/10.1038/nprot.2007.100>
- 550 Ikigai, H., Nakae, T., Hara, Y., and Shimamura, T. (1993). Bactericidal catechins damage the lipid
551 bilayer. *Biochim. Biophys. Acta* 1147(1), 132–136. [https://doi.org/10.1016/0005-2736\(93\)90323-r](https://doi.org/10.1016/0005-2736(93)90323-r)
- 552
- 553 Kim, D. O., Chun, O. K., Kim, Y. J., Moon, H. Y., and Lee, C. Y. (2003). Quantification of
554 polyphenolics and their antioxidant capacity in fresh plums. *J. Agric. Food Chem.* 51(22),
555 6509–6515. <https://doi.org/10.1021/jf0343074>
- 556 Mahboubi, M., and Mahboubi, A. (2014). Antimicrobial activity of *Capparis spinosa* as its usages
557 in traditional medicine. *Herba Polonica* 60, 39–48. <https://doi.org/10.2478/hepo-2014-0004>
- 558 Maldini, M., Foddai, M., Natella, F., Addis, R., Chessa, M., Petretto, G. L., et al. (2016).
559 Metabolomic study of wild and cultivated caper (*Capparis spinosa* L.) from different areas of
560 Sardinia and their comparative evaluation. *J. Mass Spectr.* 51(9), 716–
561 728. <https://doi.org/10.1002/jms.3830>
- 562 Mollica, A., Zengin, G., Locatelli, M., Stefanucci, A., Mocan, A., Carradori, S., et al. (2017). Anti-
563 diabetic and anti-hyperlipidemic properties of *Capparis spinosa* L.: *in vivo* and *in vitro*
564 evaluation of its nutraceutical potential. *J. Funct. Foods* 35, 32–42.
565 <https://doi.org/10.1016/j.jff.2017.05.001>
- 566 Mollica, A., Stefanucci, A., Macedonio, G., Locatelli, M., Luisi, G., Novellino, E., et al. (2019).
567 Chemical composition and biological activity of *Capparis spinosa* L. from Lipari Island. *S. Afr.*
568 *J. Bot.* 120, 135–140. <https://doi.org/10.1016/j.sajb.2018.02.397>

- 569 Nakamura, T., Daimon, T., Mouri, N., Masuda, H., and Sawa, Y. (2014). *Staphylococcus aureus*
570 and repeat bacteremia in febrile patients as early signs of sternal wound infection after cardiac
571 surgery. *J. Cardiothorac. Surg.* 9, 80. <https://doi.org/10.1186/1749-8090-9-80>
- 572 Orazi, G., and O'Toole, G. A. (2017). *Pseudomonas aeruginosa* alters *Staphylococcus aureus*
573 sensitivity to vancomycin in a biofilm model of cystic fibrosis infection. *MBio*, 8(4), e00873-
574 17. <https://doi.org/10.1128/mBio.00873-17>
- 575 Peng, LY., Yuan, M., Zhen-Qiang Cui, Zong-Mei Wu, Zhen-Jiang Yu, Song, K., Tang, B., et al.
576 (2018). Rutin inhibits quorum sensing, biofilm formation and virulence genes in avian
577 pathogenic *Escherichia coli*. *Microb Pathog.* 119, 54–59.
578 <https://doi.org/10.1016/j.micpath.2018.04.007>
- 579 Rahimi, V. B., Rajabian, A., Rajabi, H., Vosough, E. M., Mirkarimi, H. R., Hasanpour, M., et al.
580 (2020). The effects of hydro-ethanolic extract of *Capparis spinosa* (*C. spinosa*) on
581 lipopolysaccharide (LPS)-induced inflammation and cognitive impairment: evidence from *in*
582 *vivo* and *in vitro* studies. *J. Ethnopharmacol.* 256, 112706.
583 <https://doi.org/10.1016/j.jep.2020.112706>
- 584 Sabbatini, M., Magnelli, V., and Renò, F. (2021). NETosis in wound healing: when enough is
585 enough. *Cells*. 10, 494. <https://doi.org/10.3390/cells10030494>
- 586 Shreeram, D. D., Panmanee, W., McDaniel, C. T., Daniel, S., Schaefer, D. W., and Hassett, D. J.
587 (2018). Effect of impaired twitching motility and biofilm dispersion on performance
588 of *Pseudomonas aeruginosa*-powered microbial fuel cells. *J. Ind. Microbiol. Biotechnol.* 45(2),
589 103–109. <https://doi.org/10.1007/s10295-017-1995-z>
- 590 Stapleton, P. D., Shah, S., Hamilton-Miller J. M. T., Hara, Y., Nagaoka, Y., Kumagai, A., Uesato,
591 S., et al. (2004). Anti-*Staphylococcus aureus* activity and oxacillin resistance modulating
592 capacity of 3- O-acylcatechins. *Int. J. Antimicrob. Agents* (4), 374–380.
593 <https://doi.org/10.1016/j.ijantimicag.2004.03.024>
- 594 Stefanucci, A., Zengin, G., Locatelli, M., Macedonio, G., Chin-Kun Wang, Novellino, E., et al.
595 (2018). Impact of different geographical locations on varying profile of bioactives and
596 associated functionalities of caper (*Capparis spinosa* L.). *Food Chem Toxicol.* 118, 181–189.
597 <https://doi.org/10.1016/j.fct.2018.05.003>
- 598 Taguri, T., Tanaka, T., and Kouno, I. (2006). Antibacterial spectrum of plant polyphenols and
599 extracts depending upon hydroxyphenyl structure. *Biol. Pharm. Bull.* 29(11), 2226–2235.
600 <https://doi.org/10.1248/bpb.29.2226>
- 601 Thaarup, I. C., and Bjarnsholt, T. (2021). Current *in vitro* biofilm-infected chronic wound models
602 for developing new treatment possibilities. *Adv Wound Care (New Rochelle)*. 10(2), 91–102.
603 <https://doi.org/10.1089/wound.2020.1176>
- 604 Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., and Fowler, V. G., Jr. (2015).
605 *Staphylococcus aureus* infections: epidemiology, pathophysiology, clinical manifestations, and
606 management. *Clin. Microbiol. Rev.* 28(3), 603–661. <https://doi.org/10.1128/CMR.00134-14>
- 607 Tungmunnithum, D., Thongboonyou, A., Pholboon, A., and Yangsabai A. (2018). Flavonoids and
608 other phenolic compounds from medicinal plants for pharmaceutical and medical aspects: an
609 overview. *Medicines (Basel)*. 5(3), 93. <https://doi.org/10.3390/medicines5030093>
- 610 Turnbull, L., and Whitchurch, C. B. (2014). Motility assay: twitching motility. *Methods Mol. Biol.*
611 1149, 73–86. https://doi.org/10.1007/978-1-4939-0473-0_9
- 612 Wojdyło, A., Nowicka, P., Grimalt, M., Legua, P., Almansa, M. S., Amorós, A., et al. (2019).
613 Polyphenol compounds and biological activity of Caper (*Capparis spinosa* L.) flowers buds.
614 *Plants (Basel)* 8(12), 539. <https://doi.org/10.3390/plants8120539>
- 615 World Health Organization (WHO). (2013). *Regulatory situation of herbal medicines: a worldwide*
616 *review*. World Health Organization (WHO): Geneva, Switzerland

- 617 Yang, M., Zhang, C., Hansen, S. A., Mitchell, W. J., Zhang, M. Z., and Zhang, S. (2019).
618 Antimicrobial efficacy and toxicity of novel CAMPs against *P. aeruginosa* infection in a
619 murine skin wound infection model. *BMC Microbiol.* 19, 293. [https://doi.org/10.1186/s12866-](https://doi.org/10.1186/s12866-019-1657-6)
620 019-1657-6
- 621 Yung, D. B. Y., Sircombe, K. J., and Pletzer, D. (2021). Friends or enemies? The complicated
622 relationship between *Pseudomonas aeruginosa* and *Staphylococcus aureus*. *Mol. Microbiol.*
623 00, 1–15. <https://doi.org/10.1111/mmi.14699>
- 624 Zhang, H., and Ma, Z. F. (2018). Phytochemical and pharmacological properties of *Capparis*
625 *spinosa* as a medicinal plant. *Nutrients* 10(2), 116. <https://doi.org/10.3390/nu10020116>
- 626 Zengin, G., Locatelli, M., Stefanucci, A., Macedonio, G., Novellino, E., Mirzaie, S.,
627 Dvorácskó, S., et al. (2017). Chemical characterization, antioxidant properties, anti-
628 inflammatory activity and enzyme inhibition of *Ipomoea batatas* L. leaf extracts. *Int. J. Food*
629 *Prop.* 20, 1907–1919. <https://doi.org/10.1080/10942912.2017.1357127>
- 630 Zolfaghar, I., Evans, D. J., and Fleiszig, S. M. J. (2003). Twitching motility contributes to the role
631 of pili in corneal infection caused by *Pseudomonas aeruginosa*. *Infect. Immun.* 71(9), 5389–
632 5393. <https://doi.org/10.1128/IAI.71.9.5389-5393.20>
- 633
- 634

635 **FIGURE LEGENDS**

636 **Figure 1** Effect of sub-MICs of *C. spinose* aqueous extract on *P. aeruginosa* PECHA 4 motility assay;
637 representative images of swimming **(A)** and swarming **(B)** motilities on soft agar plates with diameter
638 of obtained halos and relative histograms. *significant in respect to the control ($p < 0.05$).

639 **Figure 2** Effect of sub-MICs of *C. spinose* aqueous extract on *P. aeruginosa* PECHA 4 twitching
640 assay: **(A)** representative images of macroscopic twitching assay on coltural plates; **(B)** expression of
641 *pilT* gene; **(C)** amplification chart with the Ct values of each sample of the *pilT* gene expression.

642 **Figure 3** Effect of sub-MICs of *C. spinose* aqueous extract on *S. aureus* PECHA 10 biofilm formation;
643 **(A)** biomass evaluation; **(B)** cultivable cell count (CFU/ml); **(C)** representative images (Live/Dead
644 stain) and quantitative analysis (histograms) of viable and dead cells. *significant in respect to the
645 control ($p < 0.05$).

646 **Figure 4** Effect of sub-MICs of *C. spinose* aqueous extract on *P. aeruginosa* PECHA 4 biofilm
647 formation; **(A)** biomass evaluation; **(B)** cultivable cell count (CFU/ml); **(C)** representative images
648 (Live/Dead stain) and quantitative analysis (histograms) of viable and dead cells. *significant in respect
649 to the control ($p < 0.05$).

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667 **Table 1** Total amounts ($\mu\text{g}/\text{mg}$) of phenolics in the lyophilized extract

Concentration ($\mu\text{g}/\text{mg}$)	
Chlorogenic acid	0.31 \pm 0.04
<i>p</i> -OH benzoic acid	0.35 \pm 0.07
3-OH benzoic acid	0.40 \pm 0.05
<i>p</i> -coumaric acid	0.54 \pm 0.03
Rutin	1.83 \pm 0.14
2,3-diMeO benzoic acid	0.46 \pm 0.04
Total	3.89\pm0.18

668

669

670

671 **Table 2** Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC)/
 672 Minimum Fungicidal Concentration (MFC) of *C. spinose* aqueous extract against *S. aureus* PECHA
 673 10, *P. aeruginosa* PECHA and *C. albicans* X3.

674 Amikacin and Amphotericin-B are included as control for bacteria and *C. albicans* X3, respectively.

675

Strains	MIC		MBC/MFC	
	<i>C. spinose</i> aqueous extract (%)	Amikacin/ Amphotericin-B ($\mu\text{g}/\text{ml}$)	<i>C. spinose</i> aqueous extract (%)	Amikacin/ Amphotericin-B ($\mu\text{g}/\text{ml}$)
<i>S. aureus</i> PECHA 10	6.25	16	12.50	16
<i>P. aeruginosa</i> PECHA 4	12.50	32	25	32
<i>C. albicans</i> X3	> 50	0.5	> 50	0.5

676

677

678

679

680 **Table 3** Colony Forming Units (CFUs)/mg of *S. aureus* PECHA 10 and *P. aeruginosa* PECHA 4 in
 681 presence of *Capparis spinose* aqueous extract in in forming Lubbock Chronic Wound Biofilm (LCWB)
 682 model. Amikacin (AMK) as reference control

683

684

685

686

687

688

689

690

691

692

693

694

695

	CFUs/mg LCWB (% reduction in respect to the control)	
	<i>S. aureus</i> PECHA 10	<i>P. aeruginosa</i> PECHA 4
<i>C. spinose</i>	$7.03 \times 10^{1*} \pm 6.00 \times 10^1$ (97.32* \pm 2.26)	$1.66 \times 10^{3*} \pm 3.55 \times 10^2$ (99.67* \pm 0.07)
AMK	$2.56 \times 10^2 \pm 1.03 \times 10^2$ (90.20* \pm 1.53)	$2.32 \times 10^4 \pm 5.88 \times 10^3$ (95.40* \pm 1.17)
Control	$2.62 \times 10^3 \pm 5.37 \times 10^2$	$5.03 \times 10^5 \pm 3.66 \times 10^5$

696

697

*statistically significant in respect to the control ($p < 0.05$).

698

699

700

701